Log In
Print
BCIQ
Print
Print this Print this
 

ALN-PCS, ALN-PCS02

Also known as: siRNA against hypercholesterolemia

  Manage Alerts
Collapse Summary General Information
Company Alnylam Pharmaceuticals Inc.
DescriptionSmall interfering RNA (siRNA) against proprotein convertase subtilisn/kexin type 9 (PCSK9) gene
Molecular Target Proprotein convertase subtilisin/kexin type 9 (PCSK9)
Mechanism of ActionGene silencing
Therapeutic ModalityNucleic acid: Linear RNA: siRNA
Latest Stage of DevelopmentPhase I
Standard IndicationHypercholesterolemia
Indication DetailsTreat severe hypercholesterolemia
Regulatory Designation
Partner The Medicines Co.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$205.0M

$25.0M

$180.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today